Cell-free DNA integrity (cfDNAi) could be a valuable biomarker for solid tumors, to define prognosis and response to therapy. Several elements have been studied for cfDNAi, such as specific genes involved in cancer progression or repetitive DNA sequences as surrogate markers for the whole circulating DNA.
However, the lack of a standardized method for cfDNAi evaluation remains one of its main critical issues. Apoptotic index (AI) and integrity index (II) of cfDNA could be useful biomarkers to identify the patients likely to recur, progress, or relapse, which is an urgent need in translational research in oncology.
Here it is provided an adequate method of cfDNAi analysis: a cheap and reproducible tool, robust and performable in all laboratories using a real-time PCR instrument.
cfDNA integrity Biomarker Real-time PCR Integrity index Apoptotic index
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
Schwarzenbach H, Pantel K (2015) Circulating DNA as biomarker in breast cancer. Breast Cancer Res 17:1363CrossRefGoogle Scholar
Maltoni R, Casadio V, Ravaioli S et al (2017) Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer. Oncotarget 8(10):16642–16649CrossRefGoogle Scholar
Casadio V, Calistri D, Salvi S, Gunelli R et al (2013) Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study. Biomed Res Int 2013:270457CrossRefGoogle Scholar
Salvi S, Gurioli G, Martignano F et al (2015) Urine cell-free DNA integrity analysis for early detection of prostate cancer patients. Dis Markers 2015:574120CrossRefGoogle Scholar
Casadio V, Calistri D, Tebaldi M et al (2013) Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. Urol Oncol 31(8):1744–1750CrossRefGoogle Scholar
Umetani N, Kim J, Hiramatsu S et al (2006) Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 52:1062–1069CrossRefGoogle Scholar
Madhavan D, Wallwiener M, Bents K et al (2014) Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat 146:163–174CrossRefGoogle Scholar
Chan KC, Leung SF, Yeung SW et al (2008) Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. Clin Cancer Res 14:4141–4145CrossRefGoogle Scholar
Ellinger J, Bastian PJ, Ellinger N et al (2008) Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. Cancer Lett 264:274–280CrossRefGoogle Scholar
Umetani N, Giuliano AE, Hiramatsu SH et al (2006) Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 24:4270–4276CrossRefGoogle Scholar
Kohler C, Radpour R, Barekati Z et al (2009) Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 8:105CrossRefGoogle Scholar
Elshimali YI, Khaddour H, Sarkissyan M et al (2013) The clinical utilization of circulating cell free DNA (CCF DNA) in blood of cancer patients. Int J Mol Sci 14:18925–18958CrossRefGoogle Scholar
van der Vaart M, Pretorius PJ (2008) A method for characterization of total circulating DNA. Ann N Y Acad Sci 1137:92–97CrossRefGoogle Scholar
Lehner J, Stötzer OJ, Fersching D et al (2013) Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy. Clin Chim Acta 425:206–211CrossRefGoogle Scholar